These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
156 related articles for article (PubMed ID: 1343687)
21. Protection of Aotus monkeys after immunization with recombinant antigens of Plasmodium falciparum. Enders B; Hundt E; Knapp B Mem Inst Oswaldo Cruz; 1992; 87 Suppl 3():413-22. PubMed ID: 1343721 [TBL] [Abstract][Full Text] [Related]
22. Transmission-blocking immunity against malaria and other vector-borne diseases. Kaslow DC Curr Opin Immunol; 1993 Aug; 5(4):557-65. PubMed ID: 8216932 [TBL] [Abstract][Full Text] [Related]
23. Adjuvant and carrier protein-dependent T-cell priming promotes a robust antibody response against the Plasmodium falciparum Pfs25 vaccine candidate. Radtke AJ; Anderson CF; Riteau N; Rausch K; Scaria P; Kelnhofer ER; Howard RF; Sher A; Germain RN; Duffy P Sci Rep; 2017 Jan; 7():40312. PubMed ID: 28091576 [TBL] [Abstract][Full Text] [Related]
24. A region of Plasmodium falciparum antigen Pfs25 that is the target of highly potent transmission-blocking antibodies. Stowers AW; Keister DB; Muratova O; Kaslow DC Infect Immun; 2000 Oct; 68(10):5530-8. PubMed ID: 10992450 [TBL] [Abstract][Full Text] [Related]
26. Identification of a continuous and cross-reacting epitope for Plasmodium falciparum transmission-blocking immunity. Wizel B; Kumar N Proc Natl Acad Sci U S A; 1991 Nov; 88(21):9533-7. PubMed ID: 1719534 [TBL] [Abstract][Full Text] [Related]
27. Immunological properties of recombinant proteins of the transmission blocking vaccine candidate, Pfs48/45, of the human malaria parasite Plasmodium falciparum produced in Escherichia coli. Milek RL; Roeffen WF; Kocken CH; Jansen J; Kaan AM; Eling WM; Sauerwein RW; Konings RN Parasite Immunol; 1998 Aug; 20(8):377-85. PubMed ID: 9767603 [TBL] [Abstract][Full Text] [Related]
28. Improving the malaria transmission-blocking activity of a Plasmodium falciparum 48/45 based vaccine antigen by SpyTag/SpyCatcher mediated virus-like display. Singh SK; Thrane S; Janitzek CM; Nielsen MA; Theander TG; Theisen M; Salanti A; Sander AF Vaccine; 2017 Jun; 35(30):3726-3732. PubMed ID: 28578824 [TBL] [Abstract][Full Text] [Related]
29. Transmission-blocking activity induced by malaria vaccine candidates Pfs25/Pvs25 is a direct and predictable function of antibody titer. Miura K; Keister DB; Muratova OV; Sattabongkot J; Long CA; Saul A Malar J; 2007 Aug; 6():107. PubMed ID: 17686163 [TBL] [Abstract][Full Text] [Related]
30. Antibodies to plant-produced Plasmodium falciparum sexual stage protein Pfs25 exhibit transmission blocking activity. Farrance CE; Chichester JA; Musiychuk K; Shamloul M; Rhee A; Manceva SD; Jones RM; Mamedov T; Sharma S; Mett V; Streatfield SJ; Roeffen W; van de Vegte-Bolmer M; Sauerwein RW; Wu Y; Muratova O; Miller L; Duffy P; Sinden R; Yusibov V Hum Vaccin; 2011; 7 Suppl():191-8. PubMed ID: 21266847 [TBL] [Abstract][Full Text] [Related]
31. Functional immunogenicity of baculovirus expressing Pfs25, a human malaria transmission-blocking vaccine candidate antigen. Mlambo G; Kumar N; Yoshida S Vaccine; 2010 Oct; 28(43):7025-9. PubMed ID: 20709008 [TBL] [Abstract][Full Text] [Related]
32. Immunogenicity of a recombinant malaria vaccine candidate, domain I+II of AMA-1 ectodomain, from Indian P. falciparum alleles. Lalitha PV; Biswas S; Pillai CR; Saxena RK Vaccine; 2008 Aug; 26(35):4526-35. PubMed ID: 18590786 [TBL] [Abstract][Full Text] [Related]